The team that pioneered first-generation fibroblast gene therapy has come together to build what comes next: durable, non-viral autologous and allogeneic cell medicines engineered to restore functional Collagen VII and durably treat Dystrophic Epidermolysis Bullosa (DEB) wounds, addressing both recessive (RDEB) and dominant (DDEB) forms.
Deficiency in functional Type VII Collagen causes blistering and structural detachment upon minor friction.
Dystrophic Epidermolysis Bullosa (DEB) is caused by genetic disruption across the exons, introns, and transcriptional control regions of the COL7A1 gene. In recessive DEB (RDEB), functional Type VII Collagen is absent. In dominant DEB (DDEB), mutant chains exert a dominant-negative effect that disrupts anchoring fibril assembly. IntegriGen addresses both with durable, non-viral living cell therapies.
Mutations across the 118 exons, introns, and regulatory control regions of COL7A1 eliminate functional Type VII Collagen. IntegriGen’s engineering strategy restores full-length COL7A1 expression with intact transcriptional regulation to re-establish dermal-epidermal attachment.
Topical viral-vector approaches have demonstrated clinical efficacy, but treatment may require repeated wound-specific application. Surgical cell-sheet approaches require specialized procedural logistics. These approaches do not necessarily provide a durable, resident cellular source of Collagen VII within the dermis.
By harvesting patient fibroblasts, non-virally integrating full-length COL7A1 with optimized transcription controllers, and delivering them locally, IntegriGen creates living dermal "factories" capable of sustained therapeutic Collagen VII production.
Healthy dermal fibroblasts synthesize and assemble Type VII Collagen homotrimers, forming dense looping anchoring fibrils that secure the epidermal basement membrane to the dermis.
Mutant fibroblasts fail to produce functional Type VII Collagen. Complete absence of anchoring fibrils causes severe blistering and mechanical skin detachment at the DEJ fault line.
Administered genetically modified fibroblasts continuously express and secrete full-length Type VII Collagen in situ, rebuilding anchoring fibrils and restoring mechanical dermal integrity.
Raptor OS is BioSolution Designs’ integrated technology operating system for the development of paradigm shifting advanced therapies that are large (>10kb), complex, and / or encode multiple active therapeutic effectors (multigenic). It brings together five coordinated technology pillars—Gene Delivery, Genome Context, Gene Expression, Effector Engineering, and BioManufacturing—so therapeutic programs can be designed, controlled, and translated within a single modular architecture.
Embedded Promoters, Introns, UTRs & Enhancer Elements
Advancing lead autologous candidate NTGN-001 through discovery and translational characterization.
Targeting durable COL7A1 restoration in chronic blistering wounds
Off-the-shelf stromal cell therapies for severe chronic wound beds with enhanced durable effect
IntegriGen unites key inventors, clinical manufacturing authorities, and executives who developed first-generation fibroblast therapies through the historic Fibrocell–Intrexon collaboration.
Founder & CEO of BioSolution Designs. 20+ year tenure at Intrexon (Precigen) inventing foundational platforms (UltraVector®, RheoSwitch®). Led the 2017 GenVec acquisition and AdenoVerse® platform, inventing the FDA-approved PAPZIMEOS (Aug 2025).
Former CEO of Fibrocell Science / Castle Creek leading the FCX-007 (D-Fi) RDEB Phase 1/2 trial (NCT02810951; 80% wound healing at 12 wks). Currently President & CEO of Forge Biologics and Chair of the Board of Directors for DEBRA of America.
Molecular biologist focused on design and optimization of biologics, with a focus on transition from laboratory into clinical trial initiation.
Oversees autologous cell processing, cGMP facility operations, analytical release testing, and clinical technology transfer protocols.
Synthetic biologist and systems modeler focused on gene regulation circuitry and construct optimization for large multigenic payloads.
Head of Communications & Investor Relations
Comms & Investor RelationsLeads corporate communications, investor relations, and capital strategy with extensive startup capitalization experience across deep tech and life sciences.
"Patients are our focus. Caregivers are essential partners. These directives allow us to create value for our stakeholders. We succeed together."
BioSolution Designs Studio Philosophy · Supporting Directive
We measure success not by bandage maintenance, but by genuine dermal engraftment designed to promote durable wound closure and reduce the trauma of daily dressing changes.
Every cell batch must satisfy strict Raptor OS™ enrichment thresholds before release. We prioritize product potency, genomic safety, and reproducibility over rapid clinical shortcuts.
Advanced cellular therapies must not be restricted to top-tier research hospitals. We design processes for scalable, localized delivery that reaches patients globally.
IntegriGen is actively engaging with institutional funds, accredited investors, and strategic partners to advance our next-generation living cell therapy pipeline for Dystrophic Epidermolysis Bullosa (DEB).
Complete the fields below to connect with executive leadership or request diligence credentials.